<DOC>
	<DOCNO>NCT01968980</DOCNO>
	<brief_summary>This multicenter , randomize study subject heterozygous familial hypercholesterolemia receive highly effective statin assess safety , efficacy tolerability Bococizumab ( PF-04950615 ; RN316 ) low LDL-C .</brief_summary>
	<brief_title>A 52 Week Study To Assess The Use Of Bococizumab ( PF-04950615 ; RN316 ) In Subjects With Heterozygous Familial Hypercholesterolemia</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<criteria>Treated statin . Fasting LDLC &gt; 70 mg/dL triglyceride &lt; =400 mg/dL . High high risk incur cardiovascular event . Heterozygous familial hypercholesterolemia . Pregnant breastfeeding female . Cardiovascular cerebrovascular event procedure past 30 day . Congestive heart failure NYHA class IV . Poorly control hypertension .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>High Risk cardiovascular event</keyword>
	<keyword>Heterozygous familial hypercholesterolemia</keyword>
</DOC>